CXCL16 and pachyonychia congenita: We further validated these findings using scRNA-Seq of tumor tissues from patients with PC, demonstrating that those with higher CXCL16 expression were more sensitive to gemcitabine treatment (Figure 7, B–E, and Supplemental Figure 7, I and J).